KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBITDA: 2009-2024

Historic EBITDA for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$105.2 million.

  • Nektar Therapeutics' EBITDA rose 7.78% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 35.91%. This contributed to the annual value of -$105.2 million for FY2024, which is 60.10% up from last year.
  • Nektar Therapeutics' EBITDA amounted to -$105.2 million in FY2024, which was up 60.10% from -$263.7 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' EBITDA ranged from a high of -$105.2 million in FY2024 and a low of -$446.1 million during FY2021.
  • In the last 3 years, Nektar Therapeutics' EBITDA had a median value of -$263.7 million in 2023 and averaged -$248.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first decreased by 4.94% in 2021, then spiked by 60.10% in 2024.
  • Over the past 5 years, Nektar Therapeutics' EBITDA (Yearly) stood at -$425.1 million in 2020, then decreased by 4.94% to -$446.1 million in 2021, then increased by 15.68% to -$376.2 million in 2022, then rose by 29.90% to -$263.7 million in 2023, then surged by 60.10% to -$105.2 million in 2024.